Goldfinch Bio Announces Upcoming Presentations at American Society of Human Genetics (ASHG) 2021 Meeting and American Society of Nephrology’s (ASN) Kidney Week 2021

CANNANNEW REPORT

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced upcoming presentations at the American Society of Human Genetics (ASHG) 2021 Meeting, taking place October 18-22, 2021, and at the American Society of Nephrology’s (ASN) Kidney Week 2021, taking place November 4-7, 2021. Both meetings are being held virtually. At ASHG, Goldfinch Bio will give an oral presentation showcasing insights revealed by its Kidney Genome Atlas (KGA). The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention. At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN) .1 GFB-887 is a podocyte-targeting, small molecule inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), designed specifically to treat patients with kidney diseases characterized by an over-activation of the TRPC5-Rac1 pathway; The design of the ongoing Phase 1 clinical trial of GFB-024, a peripherally restricted cannabinoid 1 (CB1) inverse agonist monoclonal antibody intended to treat patients with severe insulin resistant DN and CB1 pathway overactivation; Additional data further supporting the use of the KGA to identify APOL1 and other genetic drivers of adult proteinuric kidney disease; and New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We are excited to…

Excerpt only …
READ MORE BELOW
Source : Goldfinch Bio Announces Upcoming Presentations at American Society of Human Genetics (ASHG) 2021 Meeting and American Society of Nephrology’s (ASN) Kidney Week 2021

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.